Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Items 301–400 of 670
Nazar, W., Romantowski, J., Nazar, G., Niedoszytko, M., Braun-Dullaeus, R. C., & Daniłowicz‐Szymanowicz, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-03428-3 · Cited by 7
Recent developments of vaccines for older adults: Adjuvants and beyond
Pangrazzi, L., & Weinberger, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2517931 · Cited by 12
Cutaneous adverse reactions to coronavirus vaccines: A Saudi nationwide study
Bukhari, A., Almutlq, M. M., Dakhil, A. A. B., Alhetheli, G. I., Alfouzan, S., Alqahtani, M. A., Aljalfan, A. A. N., Almutawa, M. A., Alsubaie, F. S., & Madani, A. N. (2022) · Dermatologic Therapy · doi:10.1111/dth.15452 · Cited by 6
“psoriasis, vitiligo, Raynaud phenomenon, and severe cellulitis were reported.(4) Several cutaneous reactions have been reported after COVID-19 vaccination such as injection site reaction, exanthematous rash, urticaria, vesicular eruption, chilblain-like lesions, erythromelalgia, angioedema, erythema multiforme-like le…”
BackgroundMethodAraminda, G. N., & Ramatillah, D. L. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s2.44747 · Cited by 7
Intranasal Sendai virus‐based SARS‐CoV ‐2 vaccine using a mouse model
Morimoto, S., Saeki, K., Takeshita, M., Hirano, K., Shirakawa, M., Yamada, Y., Nakamura, S., Ozawa, F., & Okano, H. (2022) · Genes to Cells · doi:10.1111/gtc.12992 · Cited by 6
“Vaccines developed by pharmaceutical companies, including Pfizer, Moderna, and AstraZeneca, were reported to be effective in preventing severe disease and have been approved in many countries (El Sahly et al., 2021; Falsey et al., 2021; Haas et al., 2021).”
BackgroundCOVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Bayani, F., Hashkavaei, N. S., Karamian, M. R., Uskoković, V., & Sefidbakht, Y. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2170470 · Cited by 7
“…in the effort to curb the mortality rate due to viral infection was the production of multiple vaccines against SARS-CoV-2, including BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), mRNA-1273 (Moderna), and others (Baden et al., 2021; Falsey et al., 2021; Polack et al., 2020).”
BackgroundProntskus, V., Fresse, A., Yelehe‐Okouma, M., Facile, A., Pietri, T., Simon, C., Souder, C. L., Beurrier, M., & Gillet, P. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2866 · Cited by 7
Narongkiatikhun, P., Noppakun, K., Chaiwarith, R., Winichakoon, P., Vongsanim, S., Suteeka, Y., Pongsuwan, K., Kusirisin, P., Wongsarikan, N., Fanhchaksai, K., et al. (2023) · Vaccines · doi:10.3390/vaccines11040715 · Cited by 7
“Our results were similar to most of the previous studies of each vaccine regimen among the general population [8,31].”
ResultYang, M.-C., Wang, C.-C., Tang, W.-C., Chen, K.-M., Chen, C., Lin, H., Hsieh, Y., Wang, N.-H., Kuo, Y.-C., Chu, P.-T., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283473 · Cited by 8
Turley, C. B., Tables, L., Fuller, T. L., Sanders, L. J., Scott, H. M., Moodley, A., Davis, A. S. W., Leav, B. A., Miller, J. M., Schoemaker, K., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.066 · Cited by 8
Self-citationMueller-Enz, M., Woopen, C., Rahbani, G. K. A., Haase, R., Dunsche, M., Ziemssen, T., & Akgün, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1081933 · Cited by 8
Rosa, R. G., Falavigna, M., Manfio, J. L., de Araújo, C. L. P., Cohen, M. M., Barbosa, G. R. G. D. V., de Souza, A. P., Silva, F. K. R., Sganzerla, D., da Silva, M. M. D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.038 · Cited by 8
SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review
Jing, X., Han, M., Wang, X., & Zhou, L. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08553-w · Cited by 11
“12 [31] Low risk Low risk Low risk Low risk Low risk High risk”
BackgroundThe SARS-CoV-2 Variants and their Impacts
Shukri, A. M. A., Wang, S. M., Chia, S. L., & Nawi, S. F. A. M. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.3.45 · Cited by 8
Castillo, L. A., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón, L. E., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3944059 · Cited by 8
Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies
Santamaria-Castro, I., Leiva-Rebollo, R., Marín‐Wong, S., Jiménez-Guardeño, J. M., & Ortega‐Prieto, A. M. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00260-24 · Cited by 7
Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras
Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · Research · doi:10.34133/research.0099 · Cited by 9
Lien, S.-C., Shen, Y.-S., Lin, H.-Y., Wu, S., Fang, C., Chen, C.-H., Chen, Y., Chong, P. C.-S., Huang, M., Chow, Y., et al. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199101 · Cited by 6
Okuno, S., Higo, S., Kondo, T., Shiba, M., Kameda, S., Inoue, H., Tabata, T., Ogawa, S., Morishita, Y., Sun, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48084-7 · Cited by 6
“S-RBD is the major target and a common domain for various types of COVID-19 vaccines that interfere with viral receptor binding 6,26–28 .”
Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context
Rhodes, P., & Parry, P. I. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155030 · Cited by 6
Sherman, A. C., Tuan, J., Cantos, V. D., Adeyiga, O. B., Mahoney, S., Ortega‐Villa, A. M., Tillman, A., Whitaker, J. A., Davis, A. S. W., Leav, B. A., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae192 · Cited by 6
Self-citationDagotto, G., Colarusso, A., Patio, R. C., Li, D., Anioke, T., Giffin, V. M., Guan, R., Anand, T., Mbiwan, E. R., Aïd, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009644 · Cited by 6
Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines
Rhodes, P., & Parry, P. I. (2024) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479241292008 · Cited by 7
Petro-Turnquist, E. M., Bullard, B. L., Pekarek, M. J., & Weaver, E. A. (2022) · Vaccines · doi:10.3390/vaccines10060926 · Cited by 8
Pakvisal, N., Sainamthip, P., Teeyapun, N., Luangdilok, S., Wanlapakorn, N., Yorsaeng, R., Poovorawan, Y., Pakvisal, P., Susiriwatananont, T., Zungsontiporn, N., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2094149 · Cited by 6
Fibke, C. D., Joffres, Y., Tyson, J. R., Colijn, C., Janjua, N. Z., Fjell, C. D., Prystajecky, N., Jassem, A. N., & Sbihi, H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.915363 · Cited by 8
Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination
Hsieh, M.-H., & Yamaguchi, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10071641 · Cited by 6
Parai, D., Choudhary, H. R., Dash, G. C., Behera, S., Mishra, N., Pattnaik, D., Raghav, S. K., Mishra, S. K., Sahoo, S. K., Swain, A., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.942659 · Cited by 5
“0% and a maximum of 100% in severe or critical symptomatic COVID-19 at ≥15 days after the second dose (Falsey et al., 2021).”
BackgroundRao, E., Grover, P., & Zhang, H. (2022) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000125 · Cited by 7
“For people vaccinated with ChAdOx1nCoV-19, a second shot is needed to achieve full protection.[30] After their initial first vaccination, five of the 35 patients mentioned in the study above received BNT162b2 at 10 to 18 weeks later.”
BackgroundLessons from a large-scale COVID-19 vaccine trial
Mahla, R. S., & Dustin, L. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163202 · Cited by 6
Rizzo, P. A., Bellavia, S., Scala, I., Colò, F., Broccolini, A., Antonica, R., Vitali, F., Angeloni, B. M., Brunetti, V., Iorio, R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236878 · Cited by 6
Zhu, D., Hu, Y., Jiang, Z., Yang, T., Chu, K., Zhang, H., Hu, J., Meng, X., Tan, Z., Wu, J., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135929 · Cited by 7
Hyun, J. H., Park, Y., Song, Y. G., Han, S. H., Park, S. Y., Kim, S. H., Park, J. S., Jeon, S., Lee, H. S., & Lee, K. H. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0298 · Cited by 6
“7,14,15 The reason for not including the analysis after the booster shot in this study was that heterologous booster vaccination was performed among South Korean HCWs.”
Geldof, J., Truyens, M., Sabino, J., Ferrante, M., Lambert, J., Lapeere, H., Hillary, T., Laethem, A. V., de Vlam, K., Verschueren, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126351 · Cited by 6
Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report
Makiyama, A., Abe, Y., Furusawa, H., Kogami, M., Ando, T., Tada, K., Onimaru, M., Ishizu, A., Yamaji, K., & Tamura, N. (2023) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxad037 · Cited by 6
Masci, G. M., Izzo, A., Bonito, G., Marchitelli, L., Guiducci, E., Ciaglia, S., Lucchese, S., Corso, L., Valenti, A., Malzone, L., et al. (2023) · La radiologia medica · doi:10.1007/s11547-023-01664-z · Cited by 9
Marchese, A. M., Kalkeri, R., Vadivale, M., Suntronwong, N., Toback, S. L., & Poovorawan, Y. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2232020 · Cited by 6
“Viral vector COVID-19 vaccines include ChAdOx1 nCov-19 (Vaxzevria [23] and COVISHIELD [24]), an adenoviral vector developed in the UK by the University of Oxford and AstraZeneca (also licensed to Serum Institute of India) [25], and Ad26.”
BackgroundVaccination effects on reducing COVID ‐19 complications in pregnancy: A large‐scale report from Iran
Changizi, N., Eshrati, B., Salehi, M., Beheshtian, M., Jahromy, L. H., Afshar, N., Hejazi, S., Hantoushzadeh, S., Eslamian, L., Savaie, M., et al. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.15077 · Cited by 6
“25,27,33 Ac - cording to our findings, COVID-19 vaccines could also significantly decrease the risk of ICU admission in pregnant patients.”
BackgroundPorntharukchareon, T., Chartisathian, W., Navinpipat, M., Samdaengpan, C., Cheirsilpa, K., Lueprasitsakul, A., Worawichawong, S., Muangsillapasart, V., Pumuthaivirat, P., Dechates, B., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2251850 · Cited by 7
The prevention and treatment of COVID-19 in patients treated with hemodialysis
Zeng, B., Zhou, J., Peng, D., Dong, C., & Qin, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01389-9 · Cited by 9
An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines
Mathew, D. S., Pandya, T., Pandya, H., Vaghela, Y., & Subbian, S. (2023) · Biomolecules · doi:10.3390/biom13111565 · Cited by 8
Phuensan, P., Sirimongkolkasem, J., Tantawichien, T., Phannajit, J., Kerr, S. J., Hansasuta, P., Chantharit, P., Wongsa, A., Fuengfoo, P., Chittinandana, A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23246 · Cited by 6
“The regimen also showed similar vaccine efficacy in both younger (18-to 64-year-old) and older (above-65-year-old) age group [6].”
BackgroundMethodResultInfluentialSolaymani–Dodaran, M., Kalantari, S., Banihashemi, S. R., Es‐haghi, A., Noofeli, M., Mohazzab, A., Mokhberalsafa, L., Sadeghi, F., Mokarram, A. R., Hajimoradi, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27370 · Cited by 6
Park, J., & Kim, K. H. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0065 · Cited by 8
Ahmed, M. I. M., Einhauser, S., Peiter, C., Senninger, A., Baranov, O., Eser, T. M., Huth, M., Olbrich, L., Castelletti, N., Rubio‐Acero, R., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110138 · Cited by 6
Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study
Sheldrick, K. A., Meyerowitz‐Katz, G., & Tucker‐Kellogg, G. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001528 · Cited by 8
Diaphragmatic Dysfunction due to Neuralgic Amyotrophy After SARS-CoV-2 Vaccination: A Case Report
Kang, J., & Cho, J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e283 · Cited by 6
Li, J., Li, Z., Zhu, Y., Zhou, L., & Zhu, F. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0025 · Cited by 7
“1) in participants 65 years of age or older [16].”
BackgroundOng, M. J. Y., Khoo, C. S., Lee, Y. X., Poongkuntran, V., Tang, C. K., Choong, Y. J., Hod, R., & Tan, H. J. (2022) · Epilepsia Open · doi:10.1002/epi4.12658 · Cited by 6
“31,36,37 The present study did not include etiology of epilepsy as a variable as the aetiologies of several participants were yet to be identified.”
Baek, Y. J., Lee, Y.-J., Park, S. R., Kim, K. H., Beom, S., Lee, C., Shin, S. J., Rha, S. Y., Kim, S., Lee, K. H., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1541 · Cited by 6
Song, J. Y., Choi, W. S., Heo, J. Y., Kim, E., Lee, J. S., Jung, D. S., Kim, S., Park, K., Eom, J. S., Jeong, S. J., et al. (2023) · medRxiv · doi:10.1101/2023.01.31.23284895 · Cited by 6
Anywaine, Z., Serwanga, J., Ggayi, A.-B., Abaasa, A. M., Wright, D., Gombe, B., Ejou, P., Namata, T., Kigozi, A., Tukamwesiga, N., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00565-1 · Cited by 5
Pandemic vaccines: a formidable challenge for pharmacovigilance
Kiazand, A., Luther, R., Würtele, J. M., Southall, N. T., Domalik, D., & Ysander, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00178-z · Cited by 5
Serwanga, J., Oluka, G. K., Baine, C., Ankunda, V., Sembera, J., Kato, L., Katende, J. S., Odoch, G., Auma, B. O., Gombe, B., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303113 · Cited by 3
Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
Yoon, D., Jung, K., Kim, J. H., Ko, H. Y., Yoon, B., Shin, J., & CoVaSC Investigators (2024) · Emerging infectious diseases · doi:10.3201/eid3011.240610 · Cited by 6
Phadke, V. K., Gromer, D. J., Rebolledo, P. A., Graciaa, D. S., Wiley, Z., Sherman, A. C., Scherer, E. M., Leary, M., Girmay, T., McCullough, M. P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126441 · Cited by 5
Self-citationComparative efficacy of leading COVID-19 vaccines: A network meta-analysis
Rai, S., & Tripathi, S. S. (2025) · The Indian Journal of Medical Research · doi:10.25259/ijmr_750_2024 · Cited by 6
Mandal, S., Chanu, W. P., & Natarajaseenivasan, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1442101 · Cited by 6
de Gentile, A. S., Castellano, V. E., Pacchiotti, A., Weinberger, N., Menéndez, S. D., del Pino, M., Carciofi, G., Lamy, P., & Mistchenko, A. S. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100187 · Cited by 6
“Studies with other vaccine platforms also described high rates of immune response [10–12].”
Tawinprai, K., Siripongboonsitti, T., Porntharukchareon, T., Wittayasak, K., Thonwirak, N., Soonklang, K., Sornsamdang, G., Auewarakul, C. U., & Mahanonda, N. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2099380 · Cited by 6
Virtual autopsy in SARS-CoV-2 breakthrough infection: a case report
Filograna, L., Manenti, G., Grassi, S., Zedda, M., Cazzato, F., Ryan, C. P., Arena, V., Pascali, V. L., Colosimo, C., Floris, R., et al. (2022) · Forensic Imaging · doi:10.1016/j.fri.2022.200520 · Cited by 5
Scotto, R., Buonomo, A. R., Zumbo, G., Fusco, A. D., Esposito, N. D. P., Filippo, I. D., Nobile, M., Pinchera, B., Moriello, N. S., Villari, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111895 · Cited by 4
SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
Memenga, F., Kueppers, S. T., Borof, K., Kirchhof, P. F., Duengelhoef, P. M., Barten, M. J., Lütgehetmann, M., Berisha, F., Fluschnik, N., Becher, P. M., et al. (2023) · Transplant International · doi:10.3389/ti.2023.10883 · Cited by 5
Osibogun, A. O., Shuaib, F. M., Adeyeye, C. M., Onajole, A. T., Ejembi, C. L., Banwat, M., Wright, O., Mohammed, A., Adeleye, O. A., Yahya, S., et al. (2023) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_299_22 · Cited by 6
Augustinussen, M. H., Tylden, G. D., & Rinaldo, C. H. (2023) · Viruses · doi:10.3390/v15030619 · Cited by 7
“In support of this, a study by Falsey and colleagues reported a continued increase in anti-S IgG and neutralising antibodies 28 days post ChAdOx1 vaccination [6].”
ResultCOVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review
Shear, S. L., Shams, K., Weisberg, J., Hamidi, N., & Scott, S. C. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.03.006 · Cited by 6
Design of effective outpatient sentinel surveillance for COVID-19 decision-making: a modeling study
Toh, K. B., Runge, M., Richardson, R. A. K., Hladish, T. J., & Gerardin, J. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08261-5 · Cited by 5
Miyazaki, H., Watanabe, D., Ito, Y., Ikeda, S., Okamoto, N., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., & Kodama, Y. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01386-0 · Cited by 4
Tanaka, T., Tashiro, M., Ota, K., Fujita, A., Sawai, T., Kadota, J., Fukuda, Y., Sumiyoshi, M., Ide, S., Tachikawa, N., et al. (2023) · Medicine · doi:10.1097/md.0000000000034858 · Cited by 5
COVID-19 Vaccination–Related Pericarditis
Lee, N., Kim, K. H., Park, J., Cho, J. Y., Cho, S. H., Kim, D. K., Kim, S. Y., Kim, E. K., Choi, E., Choi, J., et al. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.026 · Cited by 6
Kurup, D., Wirblich, C., Diba, L. Z., Lambert, R., Watson, M., Shaikh, N., Ramage, H. R., Solomides, C., & Schnell, M. J. (2022) · Viruses · doi:10.3390/v14061126 · Cited by 6
Méndez-Lizárraga, C. A., Chacón‐Cruz, E., Carrillo-Meza, R., Hernández-Milán, N. S., Inustroza-Sánchez, L. C., Ovalle-Marroquín, D. F., Machado-Contreras, J. R., Zuñiga, O. C., Bejarano-Ramírez, V., Aguilar-Aguayo, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10081196 · Cited by 7
“The AZ from Oxford vaccine trial reported all AE with severity distinctions [36], as well as those grades 3 or higher and non-serious AE.”
BackgroundQuantitative Benefit–Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis
Son, K., Kwon, S., Na, H.-J., Baek, Y., Kim, I., & Lee, E. (2022) · Vaccines · doi:10.3390/vaccines10122029 · Cited by 6
“For pre-authorization benefit and risk criteria, input data were retrieved from clinical trials searched in MEDLINE and regulatory documents submitted for emergency use approval (BNT162b2 [16,17], mRNA-1273 [18,19], ChAdOx1-S [20,21], and Ad26.”
MethodKamal, S. M., Naghib, M. M., Daadour, M., Alsuliman, M. N., Alanazi, Z. A., Basalem, A., Alaskar, A. M., & Saed, K. (2023) · Viruses · doi:10.3390/v15020326 · Cited by 5
Bannick, M. S., Gao, F., Brown, E. R., & Janes, H. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad046 · Cited by 5
Self-citationEzzikouri, S., Raji, T., Majidi, H., Redwane, S., Aqillouch, S., Abdulaziz, M., Aragaw, M., Fallah, M. P., Sembuche, S. L., Batcho, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58498-6 · Cited by 7
Yamaguchi, D., Shimizu, R., & Kubota, R. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13164 · Cited by 6
Rappaport, A., Hong, S., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.08.467773 · Cited by 5
DNA-based vaccines: Advances, applications, and future prospects
Zhou, Z. P., Chen, Z. R., Bandara, R. A., Duan, R. C., Cao, H., Liu, J., & Hu, J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102025 · Cited by 9
“7,8 While most of these vaccines remain in early-phase or preclinical studies, some have made significant progress.”
Göttig, L., & Schreiner, S. (2024) · Tumour Virus Research · doi:10.1016/j.tvr.2024.200277 · Cited by 4
Hwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4
Wong, J., Donegan, K. L., Harrison, K., Jan, T., Cave, A. C., & Tregunno, P. (2025) · Drug Safety · doi:10.1007/s40264-025-01579-w · Cited by 4
“…clinical trials with higher reporting of local and systemic events following administration of the Pfizer mRNA vaccine in younger individuals and after a second dose [30] and in younger individuals after a first dose following administration of the AstraZeneca adenoviral vectored vaccine [31].”
Giugliano, F., Zucali, P. A., Galli, G., Ballatore, Z., Corti, C., Aliaga, P. T., Uliano, J., Vivanet, G., Curigliano, G., Conforti, F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.011 · Cited by 5
“The rate and the spectrum of G1/G2-reported AE was consistent with those reported in the general population [7-9].”
SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
Syahniar, R., & Kharisma, D. S. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.2.173 · Cited by 6
“However, concerns have been raised regarding the reduction of vaccine efficacy against globally emerging variants [10-13].”
BackgroundMethodSonoyama, T., Iwata, S., Shinkai, M., Iwata‐Yoshikawa, N., Shiwa-Sudo, N., Hemmi, T., Ainai, A., Nagata, N., Matsunaga, N., Tada, Y., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.025 · Cited by 3
Hirotsu, Y., Sugiura, H., Takatori, M., Mochizuki, H., & Omata, M. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01316-23 · Cited by 5
O’Reilly, S. R., Kenny, G., Alrawahneh, T., Francois, N., Gu, L., Angeliadis, M., d’Autume, V. D. M., Leon, A. G., Feeney, E. R., Yousif, O., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294262 · Cited by 4
“During initial COVID-19 vaccine clinical trials, high infection and hospitalisation rates allowed for collection of data on protection from infection or severe disease [57–60].”
BackgroundLee, C., Otunla, A. A., Brennan, I., Aronson, J. K., & Nunan, D. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15992 · Cited by 4
Hossaini, S., Keramat, F., Cheraghi, Z., Zareie, B., & Doosti‐Irani, A. (2023) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2023.128 · Cited by 6
Kuo, Y., Kang, C., Lai, Z., Huang, T., Tzeng, S., Hsu, C., Chen, S., Hsieh, S., Chia, J., Jung, C., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29556 · Cited by 4
“33,34 However, our study also identified an increase in anti ‐ PF4 in some individuals (75.68%, 28 in 37) who received two adenoviral vector vaccines without clinical VITT.”
BackgroundInfluentialThe fast-track development of COVID-19 vaccines
El‐Maradny, Y. A., Ramadan, A. A., Chavda, V. P., Balar, P. C., & Redwan, E. M. M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00027-8 · Cited by 6
Stanley, A. M., Aksyuk, A. A., Wilkins, D. E., Green, J. A., Lan, D., Shoemaker, K., Tieu, H., Sobieszczyk, M. E., Falsey, A. R., & Kelly, E. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401728 · Cited by 4
“The analyses in this manuscript are restricted to participants in the US enrolled sub-study population, as previously detailed (9, 10, 34).”
BackgroundMethodInfluentialSelf-citationMateo‐Urdiales, A., Fabiani, M., Mayer, F., Sacco, C., Belleudi, V., Cas, R. D., Fotakis, E. A., Angelis, L. D., Cutillo, M., Petrone, D., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-19071-y · Cited by 4
Jhanwar, A., Sharma, D., & Das, U. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134850 · Cited by 5
Deming, M. E., Brown, E. R., McArthur, M. A., Schrag, S. J., Arvay, M. L., Humphrys, M. S., Ravel, J., Adelglass, J. M., Essink, B. J., Musante, D. B., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.100984 · Cited by 5
“19,20 The efficacy of Ad26.”
Self-citationSerna, Á., Navarro, V., Jiménez, M., Iraola‐Truchuelo, J., Bosch, M., García-Herce, C., Falcó-Roget, A., Albasanz‐Puig, A., Ruíz-Camps, I., Andrés, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015406 · Cited by 5
Valletta, M., Canevelli, M., D’Antonio, F., Trebbastoni, A., Talarico, G., Campanelli, A., Monti, M. S., Vita, A. D., Salati, E., Imbriano, L., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220077 · Cited by 5
“S) [28] Johnson & Johnson 43,783 52 (18–100) Yes* Not reported AZD1222 (ChAdOx1 nCoV-19) [29] Oxford, AstraZeneca 32,379 51 (18–100) No 15 (< 0.”
Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan
Miyazaki, H., Watanabe, D., Ito, Y., Okamoto, N., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., & Kodama, Y. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07703-5 · Cited by 3
He, Q., Liu, S., Liang, Z., Lu, S., Cun, W., & Mao, Q. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2152388 · Cited by 4
“[3] Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al.”
Background
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.